QUALITY OF CARBAMAZEPINE TABLETS IN NAIROBI COUNTY BY: KAINGU WINNIE MSINDA U29/2014/2010 SUPERVISOR: DR. K.O. ABUGA OCTOBER 2014.

Slides:



Advertisements
Similar presentations
Dr. Birgit Schmauser, BfArM, Bonn
Advertisements

Slide 1 of 16 Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community Dar Es.
Statistical Evaluation of Dissolution for Specification Setting and Stability Studies Fasheng Li Associate Director, Pharmaceutical Statistics Worldwide.
 AUTHOR- Musiba Baliruno Denis, B.pharm (MUST) SUPERVISORS ;  Prof. K.A.M. Kuria, PhD - Department of Pharmaceutics and Pharmacy Practice, University.
Statistical Approaches to Addressing the Requirements of the New FDA Process Validation Guidance for Small Molecules 1 Jason Marlin, MS/T Statistics, Eli.
TWS SAMPLE TEMPLATE Prepared by: Dr. Michelle Nieves Cintron.
Finished Pharmaceutical Product Specifications
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
By Timina Olive Kayaviri Supervisor : Dr. Amugune
BY: PATEL MINAL NARAN U29/35243/2010 SUPERVISOR: DR. P. M. NJOGU
HPLC ANALYSIS OF AZITHROMYCIN SUSPENSIONS AND TABLETS
Effects of Anti-Epileptic Drugs (AED), Phenytoin and Carbamazepine, on Calcium Transport in Caco-2 Cells, an Immortalized Human Intestinal Cell Line Melinda.
Determine impurity level in relevant batches1
POST MARKET SURVEILLANCE OF MEFENAMIC ACID CAPSULES AND TABLETS RETAILING IN NAIROBI, KENYA Research by : Khushali Naran Pindoria U29/35778/2010 Supervisor:
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Enhancement of Dissolution and Release Rate of Piroxicam From Witepsol W35 Suppository Base Using Lyophilized Inclusion Adduct of Piroxicam With Skimmed.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
A COMPARATIVE STUDY ON THE IN VITRO DISSOLUTION PROFILES OF COMMERCIALLY AVAILABLE CLARITHROMYCIN ORAL DOSAGE FORMS IN NAIROBI COUNTY, KENYA By: Manani.
Abwova Veronica Vugutsa B. Pharm
Office of New Drug Chemistry, OPS, CDER, Food and Drug Administration Establishing Dissolution Specification Current CMC Practice Vibhakar Shah, Ph.D.
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
PART-TIME JOB AMONG UMP’S STUDENTS DURING STUDY TIME Presented By: NURUL AIN FARIDAH HANUM NURUL NAJWA.
B. Neidhart, W. Wegscheider (Eds.): Quality in Chemical Measurements © Springer-Verlag Berlin Heidelberg 2000 D. RuddThe Importance of “Good” Measurements.
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
A RETROSPECTIVE STUDY OF THE PRESCRIBING PATTERN OF ANTICANCER DRUGS AT THE KENYATTA NATIONAL HOSPITAL DURING THE PERIOD JANUARY 2014 TO JULY 2014 By Nyamai.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
COMPARATIVE IN VITRO EVALUATION OF GENERIC CIPROFLOXACIN HYDROCHLORIDE TABLETS IN KENYA BY DANIEL MINYETO U59/81286/2012 Department of Pharmaceutical Chemistry.
A DONE BY: RONO KIPROTICH VICTOR U29/28970/2009 A COMPARATIVE STUDY ON DISSOLUTION PROFILES OF AMOXICILLIN IN AMOXICILLIN CONTAINING CAPSULES AVAILABLE.
Improving solubility and cellular absorption of Paclitaxel with solid lipid nanoparticles and cyclodextrin Jong-Suep Baek, Jae-Woo So, Ji-Sook Hwang, Cheong-Weon.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Quality control Lecture 1.
5th - 7th November 2007 Dar es Salaam, Tanzania1 WHO prequalification A Kenyan experience Dr. H.K. Chepkwony, PhD Director, National Quality Control Laboratory.
Formulation factors By Dr. A. S. Adebayo.
Enteric-coated alendronate sodium solid lipid nanoparticles; a novel formula to overcome barriers for the treatment of osteoporosis By Funded Project.
Assessment of Interchangeable Multisource Medicines BCS-Biowaivers - Template Dr. Henrike Potthast Training workshop: Assessment of.
1 Abu Alam Ph.D. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 23, 2008.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
Formulation, Characterization of Pellets of Duloxetine Hydrochloride by Extrusion and Spheronization Prof. V. R. Sinha University Institute of Pharmaceutical.
The Value of Digital Photography By Louise Rutherford and Dean Hatt.
Seizure Dr. Shreedhar Paudel May, Seizure….. A seizure is a sudden disruption of the brain's normal electrical activity accompanied by altered consciousness.
Effects of STS Dose and Duration of Exposure on the Post Harvest Physiology of Lisianthus (Eustoma grandiflorum) Cut Flowers By: Winnie Wanjiku M. A22/0102/2007.
The Biopharmaceutical Classification System (BCS)
Introduction What is a Biowaiver?
Modified release products. Considerations in the evaluation of modified release products Requirements for preparing extended release products. The bioavailability.
Quality control Lecture 1.
Quality Assurance of Medicines under Universal Health Coverage Program by Siriwat Tiptaradol (Presenter) Duangporn Abhigantaphand Sooksri Ungboriboonpisal.
BSC Biowaiver: Components, Requirements and Criteria
*M.Pharmaceutics (3rd Semester), Anand Pharmacy College, Anand.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
1/20 PRESENTED BY BRAHMABHATT BANSARI K. M. PHARM DEPARTMENT OF PHARMACEUTICS AND PHARMACEUTICAL TECHNOLGY L. M. COLLEGE OF PHARMACY.
Inclusion Complexes of Piroxicam with B-Cyclodextrin Derivatives
Introduction What is a Biowaiver?
HPLC ANALYSIS OF AZITHROMYCIN SUSPENSIONS AND TABLETS
FORMULATION AND IN VITRO EVALUATION OF ATORVASTATIN SOLID DISPERSION
Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.
FLIPPED CLASSROOM ACTIVITY TABLETS QUALITY CONTROL TESTS
The Effect of Caffeine and Ephedrine Combination on Weight Loss and Lipid Profile of Newzealand Rabbits.
Quality control Lecture 1.
Management Considerations in Epilepsy Among Long-Term Care Residents
J.Preethi*, P. Madhu, K. Arshad Ahmed Khan.
Clinical Challenges in Epilepsy
Pediatric Formulation Development - A quality perspective
Quality control Lecture 1.
Evaluation of tablet dosage form 5) dissolution
Formulation factors By Dr. A. S. Adebayo.
Canonical Correlation Analysis
Dr. Basavaraj K. Nanjwade M. Pharm, PhD. Department of Pharmaceutics
Fenofibrate USP (Micronized, control)
Presentation transcript:

QUALITY OF CARBAMAZEPINE TABLETS IN NAIROBI COUNTY BY: KAINGU WINNIE MSINDA U29/2014/2010 SUPERVISOR: DR. K.O. ABUGA OCTOBER 2014

INTRODUCTION Epilepsy: Brain disorder - recurrent seizures due to disturbed brain activity Seizures accompanied by loss of the functions Treatment: phenobarbitone, phenytoin, ethosuximide, carbamazepine, gabapentin Carbamazepine - commonest drug in Kenya Quality assessment parameters: Dissolution, content, friability

STUDY JUSTIFICATION Quality medicines – pillar in health care Need for continuous PMS of medicines Carbamazepine occurs as 4 polymorphs with variable solubilities Previous studies: dissolution problems – effect on oral bioavailability Interconversion can occur during storage and manufacture

OBJECTIVES General objective: To carry out quality control of carbamazepine tablets in Nairobi County Specific objectives: To sample carbamazepine 200 mg tablets from pharmacies in Nairobi County To carry out assay and dissolution on the samples as per USP specifications

METHODOLOGY Sampling - done in Nairobi County, 9 brands purchased Reference standard donated by NQCL, potency 99.5% Assay- USP (2009) HPLC method Dissolution- USP (2009) method Modifications made on both methods

RESULTS AND DISCUSSION I: ASSAY RESULTS SAMPLE CODE NRB 001 NRB 002 NRB 003 NRB 004 NRB 005 %LC S/D n=64333

RESULTS AND DISCUSSION II: ASSAY RESULTS CTD.. SAMPLE CODE NRB 006NRB 007NRB 008NRB 009 %LC S/D n=3336

RESULTS AND DISCUSSION III: ASSAY CTD.... Four samples passed: NRB 002, NRB 004NRB 007 and NRB 008 Five samples failed :NRB 001, NRB 003, NRB 005, NRB 006 and NRB 009 Samples that failed contained high % LCS

RESULTS AND DISCUSSION IV DISSOLUTION : % OF DRUG RELEASED.

RESULTS AND DISCUSSION V: DISSOLUTION PROFILES

RESULTS AND DISCUSSION VI: DISSOLUTION CONT... Products attained efficient release of carbamazepine. At least 45% of the dose was released within 15 min At least 75% of the dose within 60 min Carbamazepine is insoluble in pure water but soluble in SLS

CONCLUSION 44% of samples complied with assay > 55% products contained high %LC Products had good dissolution attributes Variations in dissolution among samples observed Bioavailability investigation could explain effects in vivo

RECOMMENDATIONS Analyse all nine samples Further studies

QUESTIONS?